All In Biotech

Drug Trial Radar · NCT05283720

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

264

Actual

Start

Jun 14, 2022

Primary completion

Nov 2032

Study completion Nov 2032

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Mar 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 496 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described below: 1: Oral lenalidomide in participants (PPTS) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in PPTS with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in PPTS with newly diagnosed treatment-naïve DLBCL, or completion of treatment in 3B; 4: Oral CC-99282 in PPTS with R/R DLBCL; 5: Oral CC-99282 in PPTS with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in PPTS with R/R mantle cell lymphoma (MCL). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Non-Hodgkin Lymphoma

Interventions

  • EpcoritamabDrug

    Subcutaneous Injection (SC)

  • LenalidomideDrug

    Oral; Capsule

  • IbrutinibDrug

    Oral; Capsule

  • RituximabDrug

    Intravenous (IV); Injection

  • CyclophosphamideDrug

    IV; Injection

  • Doxorubicin Hydrochloride [HCl]Drug

    IV; Injection

  • PrednisoneDrug

    Oral; Tablet

  • Polatuzumab VedotinDrug

    IV; Injection

  • CC-99282Drug

    Oral; Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 5 Years

Locations

76 sites in 13 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center - North Campus /ID# 242219

    Tucson, Arizona

  • Yale University School of Medicine /ID# 242089

    New Haven, Connecticut

  • Christiana Care Health Service /ID# 242301

    Newark, Delaware

  • Tampa General Hospital /ID# 246748

    Tampa, Florida

  • Winship Cancer Institute of Emory University /ID# 242153

    Atlanta, Georgia

  • University of Maryland, Baltimore /ID# 242218

    Baltimore, Maryland

  • Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144

    Kansas City, Missouri

  • Northwell Health - Monter Cancer Center /ID# 245435

    Lake Success, New York

  • Icahn School of Medicine at Mount Sinai /ID# 242123

    New York, New York

  • Novant Health Presbyterian Medical Center /ID# 242148

    Charlotte, North Carolina

  • East Carolina University - Brody School of Medicine /ID# 242506

    Greenville, North Carolina

  • Novant Health Forsyth Medical Center /ID# 242198

    Winston-Salem, North Carolina

  • Thomas Jefferson University Hospital /ID# 242077

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center /ID# 242106

    Philadelphia, Pennsylvania

  • Thompson Cancer Survival Ctr /ID# 242150

    Knoxville, Tennessee

  • Joe Arrington Cancer Research /ID# 242226

    Lubbock, Texas

  • Swedish Medical Center - Seattle /ID# 242269

    Seattle, Washington

  • MultiCare Institute for Research and Innovation /ID# 242127

    Tacoma, Washington

  • Beijing Cancer Hospital /ID# 252303

    Beijing, Beijing Municipality, China

  • Fudan University Shanghai Cancer Center /ID# 252292

    Shanghai, Shanghai Municipality, China

  • Fakultni nemocnice Hradec Kralove - Sokolska /ID# 241722

    Hradec Králové, Czechia

  • Fakultni Nemocnice Brno - Jihlavska /ID# 242683

    Brno, Brno-mesto, Czechia

  • Fakultni Nemocnice Ostrava /ID# 242684

    Ostrava, Ostrava-mesto, Czechia

  • Vseobecna Fakultni nemocnice v Praze /ID# 242685

    Prague, Praha 17, Czechia

  • Aarhus Universitetshospital - Skejby /ID# 242670

    Aarhus, Central Jutland, Denmark

  • Aalborg University Hospital /ID# 242734

    Aalborg, North Denmark, Denmark

  • Hopital Saint-Louis /ID# 242336

    Paris, France

  • CHU Clermont-Ferrand /ID# 242344

    Clermont, Auvergne-Rhône-Alpes, France

  • CHU de Rennes - PONTCHAILLOU /ID# 242339

    Rennes, Brittany Region, France

  • Hopital Pitie Salpetriere /ID# 242343

    Paris, Île-de-France Region, France

  • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 242342

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

  • CHRU Lille - Hopital Claude Huriez /ID# 242335

    Lille, Nord, France

  • IUCT Oncopole /ID# 242340

    Toulouse, Occitanie, France

  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 242337

    Créteil, Paris, France

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 242345

    Nantes, Pays de la Loire Region, France

  • HCL - Hopital Lyon Sud /ID# 242349

    Pierre-Bénite, Rhone, France

  • Universitaetsklinikum Ulm /ID# 244265

    Ulm, Baden-Wurttemberg, Germany

  • Klinikum Augsburg /ID# 244523

    Augsburg, Bavaria, Germany

  • Universitaetsklinikum Regensburg /ID# 244517

    Regensburg, Bavaria, Germany

  • Universitaetsklinikum Wuerzburg /ID# 245453

    Würzburg, Bavaria, Germany

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.